Patent · US Active

Inhibition of complement activation

US7439331B2 · kind B2 · utility

33Cited by

12References

6Claims

0Family size

Assignee

Genentech, Inc. · US

Inventors

Michael S. C. Fung · Houston, US
William Sun · Bellaire, US
Cecily R. Y. Sun · Bellaire, US

Key dates

Filing date	Jun 29, 2006
Grant date	Oct 21, 2008
Priority date	—
Expiry date	Sep 24, 2026

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.